Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSE-MI 2
2025-524320-21-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylprednisolone sodium succinate in myocardial infarction (MI) (2 arms), sponsored by Rigshospitalet. Primary endpoint: All-cause mortality. Planned start Apr 2026; status: authorised.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2025-524320-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524320-21-00.